Osmetech plc (LSE:OMH) won Food & Drug Administration 510(k) clearance for its eSensor diagnostic for thrombophilia, a hereditary condition involving a propensity to develop blood clots.

The British company, which has operations in Rockland, Mass., said the test is a molecular diagnostic designed to detect four genetic markers associated with thrombosis. President and CEO Faiz Kayyem said the company believes it’s the first and only test to win FDA clearance for the four markers associated with thrombophilia, according to a press release.